Cart
×
Santhera Update on SIDEROS Clinical Trial
View Santhera’s Duchenne Community Letter
cTAP Publishes Comprehensive Analysis of the North Star Ambulatory Assessment (NSAA), a Newly Adopted Primary Outcome Measure in Clinical Trials of Patients with Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, global coalition in Duchenne muscular dystrophy (DMD), publishes research in the journal PLOS ONE providing quantitative insights to assist the […]
Santhera Fall Update to the DMD Community
View the Santhera Fall Update HERE.
Italfarmaco Fall Newsletter – Givinostat Program
View the Italfarmaco Fall Newsletter HERE.
Sarepta U.S. Patient Affairs – Newsletter for the Duchenne Community
View the Sarepta Summer 2019 Newsletter HERE.
Catabasis Connection – Phase 3 PolarisDMD trial for edasalonexent
The latest edition of the Catabasis Connection newsletter discusses Phase 3 PolarisDMD trial for edasalonexent in Duchenne. Read the full newsletter here.
WAVE Open Letter to Community
WAVE Open Letter to Community
Catabasis Connection – March 2019
In the latest Catabasis Connection, they take us behind-the-scenes with the PolarisDMD experience. Learn what it’s like to participate in their PolarisDMD clinical trial. Read the full newsletter here.
The Phase 3 PolarisDMD Trial Goes Global
With a flurry of recent activity, 17 trial sites are now open for enrollment. We are especially excited to share that our first international sites in Canada and Australia have […]